FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2361092114> ?p ?o ?g. }

• W2361092114 endingPage "4" @default.
• W2361092114 startingPage "421" @default.
• W2361092114 abstract "The purpose of this study was to investigate the prognosis of acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), lymphoid antigen-positive acute myeloid leukemia (Ly + AML), myeloid antigen-positive acute leukemia (My + ALL) and biphenotypic acute leukemia (BAL). Immunophenotyping was performed on medullary specimens of 197 acute leukemia (AL) patients by using three-color flow cytometry analysis and CD45/SSC gating. The scoring systems proposed by EGIL was adopted to classify the AL patients into five groups: 43 of ALL, 53 of AML, 53 of My + ALL, 39 of Ly + AML and 9 of BAL patients. The results showed that in Ly + AML, CD7 was the most common (53.8%) as compared to other lymphoid markers, however, in My + ALL CD13 was the most common (47.2%) as compared to other myeloid markers. Compared with Ly + AML, My + ALL had higher incidences of enlargement of liver, spleen and lymphnodes significantly (P<0.05). As for the case numbers of WBC counts > 100 x 10(9)/L, the positive rate of CD34 and the complete remission rate there was no obvious difference between groups of Ly + AML and My + ALL (P>0.05). As for incidences of enlargement of liver, spleen and lymphnodes, the case numbers of WBC counts > 100 x 10(9)/L, the positive rate of CD34 and complete remission rate, no obvious difference was found between ALL and My + ALL (P>0.05). Compared with AML, Ly + AML had lower complete remission rate significantly (P<0.05). As for incidences of enlargement of liver, spleen and lymphnodes, the case numbers of WBC counts > 100 x 10(9)/L and the positive rate of CD34, no obvious difference was found between AML and Ly + AML (P>0.05). Compared with Ly + AML and My + ALL, BAL showed no significant difference in complete remission rate (P>0.05) because the number of BAL patients was too small. It is concluded that since Ly + AML has lymphoid markers, and the prognosis of Ly + AML is worse than AML, the clinical therapy for Ly + AML should contain both AML and ALL. Though My + ALL had myeloid markers, no significant difference was found between My + ALL and ALL, it might be supposed that their therapy could be the same." @default.
• W2361092114 created "2016-06-24" @default.
• W2361092114 creator A5011083752 @default.
• W2361092114 creator A5037458498 @default.
• W2361092114 creator A5076695031 @default.
• W2361092114 creator A5085383621 @default.
• W2361092114 date "2007-04-01" @default.
• W2361092114 modified "2023-10-18" @default.
• W2361092114 title "[Clinical study on prognosis of acute leukemia subtypes Ly + AML and My + ALL]." @default.
• W2361092114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17493361" @default.
• W2361092114 hasPublicationYear "2007" @default.
• W2361092114 type Work @default.
• W2361092114 sameAs 2361092114 @default.
• W2361092114 citedByCount "0" @default.
• W2361092114 crossrefType "journal-article" @default.
• W2361092114 hasAuthorship W2361092114A5011083752 @default.
• W2361092114 hasAuthorship W2361092114A5037458498 @default.
• W2361092114 hasAuthorship W2361092114A5076695031 @default.
• W2361092114 hasAuthorship W2361092114A5085383621 @default.
• W2361092114 hasConcept C10205521 @default.
• W2361092114 hasConcept C126322002 @default.
• W2361092114 hasConcept C196166836 @default.
• W2361092114 hasConcept C203014093 @default.
• W2361092114 hasConcept C2776863199 @default.
• W2361092114 hasConcept C2778461978 @default.
• W2361092114 hasConcept C2778729363 @default.
• W2361092114 hasConcept C2779282312 @default.
• W2361092114 hasConcept C2780931953 @default.
• W2361092114 hasConcept C28328180 @default.
• W2361092114 hasConcept C54355233 @default.
• W2361092114 hasConcept C553184892 @default.
• W2361092114 hasConcept C71924100 @default.
• W2361092114 hasConcept C86803240 @default.
• W2361092114 hasConcept C90924648 @default.
• W2361092114 hasConceptScore W2361092114C10205521 @default.
• W2361092114 hasConceptScore W2361092114C126322002 @default.
• W2361092114 hasConceptScore W2361092114C196166836 @default.
• W2361092114 hasConceptScore W2361092114C203014093 @default.
• W2361092114 hasConceptScore W2361092114C2776863199 @default.
• W2361092114 hasConceptScore W2361092114C2778461978 @default.
• W2361092114 hasConceptScore W2361092114C2778729363 @default.
• W2361092114 hasConceptScore W2361092114C2779282312 @default.
• W2361092114 hasConceptScore W2361092114C2780931953 @default.
• W2361092114 hasConceptScore W2361092114C28328180 @default.
• W2361092114 hasConceptScore W2361092114C54355233 @default.
• W2361092114 hasConceptScore W2361092114C553184892 @default.
• W2361092114 hasConceptScore W2361092114C71924100 @default.
• W2361092114 hasConceptScore W2361092114C86803240 @default.
• W2361092114 hasConceptScore W2361092114C90924648 @default.
• W2361092114 hasIssue "2" @default.
• W2361092114 hasLocation W23610921141 @default.
• W2361092114 hasOpenAccess W2361092114 @default.
• W2361092114 hasPrimaryLocation W23610921141 @default.
• W2361092114 hasRelatedWork W2100322135 @default.
• W2361092114 hasRelatedWork W2235057538 @default.
• W2361092114 hasRelatedWork W2334836894 @default.
• W2361092114 hasRelatedWork W2377296402 @default.
• W2361092114 hasRelatedWork W2385791153 @default.
• W2361092114 hasRelatedWork W2387946178 @default.
• W2361092114 hasRelatedWork W2402352172 @default.
• W2361092114 hasRelatedWork W2747100245 @default.
• W2361092114 hasRelatedWork W3031747321 @default.
• W2361092114 hasRelatedWork W4286801044 @default.
• W2361092114 hasVolume "15" @default.
• W2361092114 isParatext "false" @default.
• W2361092114 isRetracted "false" @default.
• W2361092114 magId "2361092114" @default.
• W2361092114 workType "article" @default.